Stupor, rigidity, agitation, and hyperthermia.
Safinamide should not be given in combination with meperidine.
Source: G&G 14e · p419, p424
MAO-B Inhibitor · Parkinson's disease treatment
Selectively inhibits monoamine oxidase B (MAO-B), which can increase dopamine (DA) levels.
Stupor, rigidity, agitation, and hyperthermia.
Safinamide should not be given in combination with meperidine.
Source: G&G 14e · p419, p424
Drug interaction classified as: others
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: absorption
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team